Stock 000627 HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hubei Biocause Pharmaceutical Co., Ltd.

Equities

000627

CNE000000F48

Life & Health Insurance

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
2.35 CNY -3.29% Intraday chart for Hubei Biocause Pharmaceutical Co., Ltd. +1.29% -17.25%
Apr. 29 Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 27,717 34,782 24,061 16,353 15,612 14,031
Enterprise Value (EV) 1 14,167 27,982 4,655 8,772 17,373 11,297
P/E ratio 20.8 x 19.6 x 40.6 x 33.1 x 52.7 x -21.8 x
Yield 0.53% 1.85% 0.21% 0.15% 3.48% -
Capitalization / Revenue 0.93 x 0.7 x 0.59 x 0.34 x 0.32 x 0.29 x
EV / Revenue 0.47 x 0.56 x 0.11 x 0.18 x 0.35 x 0.23 x
EV / EBITDA 5.18 x 7.94 x 4 x 22.6 x 88.3 x -6.35 x
EV / FCF 2.54 x 36.8 x -0.45 x -4.6 x -7.69 x 1.3 x
FCF Yield 39.3% 2.72% -220% -21.7% -13% 76.7%
Price to Book 1.46 x 1.64 x 1.14 x 0.73 x 0.73 x 0.68 x
Nbr of stocks (in thousands) 4,940,629 4,940,629 4,940,629 4,940,629 4,940,629 4,940,629
Reference price 2 5.610 7.040 4.870 3.310 3.160 2.840
Announcement Date 4/28/19 4/14/20 4/29/21 4/29/22 4/21/23 4/29/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 29,879 49,673 41,128 48,697 49,312 48,278
EBITDA 1 2,733 3,523 1,163 388.8 196.8 -1,778
EBIT 1 2,640 3,444 1,100 300.6 105.9 -1,880
Operating Margin 8.84% 6.93% 2.67% 0.62% 0.21% -3.89%
Earnings before Tax (EBT) 1 2,636 3,633 1,449 343.1 224.8 -1,868
Net income 1 1,327 1,776 580.3 470.7 274.1 -651.8
Net margin 4.44% 3.58% 1.41% 0.97% 0.56% -1.35%
EPS 2 0.2700 0.3600 0.1200 0.1000 0.0600 -0.1300
Free Cash Flow 1 5,572 761.2 -10,255 -1,907 -2,260 8,664
FCF margin 18.65% 1.53% -24.94% -3.92% -4.58% 17.95%
FCF Conversion (EBITDA) 203.91% 21.61% - - - -
FCF Conversion (Net income) 420.05% 42.86% - - - -
Dividend per Share 2 0.0300 0.1300 0.0100 0.005000 0.1100 -
Announcement Date 4/28/19 4/14/20 4/29/21 4/29/22 4/21/23 4/29/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 1,760 -
Net Cash position 1 13,550 6,800 19,405 7,582 - 2,735
Leverage (Debt/EBITDA) - - - - 8.945 x -
Free Cash Flow 1 5,572 761 -10,255 -1,907 -2,260 8,664
ROE (net income / shareholders' equity) 9.02% 9.67% 3.24% 2.44% 1.42% -3.76%
ROA (Net income/ Total Assets) 1.04% 1.12% 0.31% 0.07% 0.02% -0.4%
Assets 1 128,104 158,227 187,736 630,983 1,146,657 163,841
Book Value Per Share 2 3.840 4.300 4.280 4.560 4.330 4.170
Cash Flow per Share 2 3.700 2.630 5.440 4.710 5.330 5.700
Capex 1 275 717 320 287 135 67.5
Capex / Sales 0.92% 1.44% 0.78% 0.59% 0.27% 0.14%
Announcement Date 4/28/19 4/14/20 4/29/21 4/29/22 4/21/23 4/29/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Life & Health Insurance

1st Jan change Capi.
HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD. Stock Hubei Biocause Pharmaceutical Co., Ltd.
-17.25% 1.66B
METLIFE, INC. Stock MetLife, Inc.
+8.35% 51.82B
AFLAC INCORPORATED Stock Aflac Incorporated
+5.19% 49.81B
MANULIFE FINANCIAL CORPORATION Stock Manulife Financial Corporation
+22.68% 47.26B
PRUDENTIAL FINANCIAL, INC. Stock Prudential Financial, Inc.
+13.63% 42.91B
GENERALI Stock Generali
+22.32% 39.1B
SUN LIFE FINANCIAL INC. Stock Sun Life Financial Inc.
+0.57% 29.53B
GREAT-WEST LIFECO INC. Stock Great-West Lifeco Inc.
-2.46% 29.24B
PRUDENTIAL PLC Stock Prudential plc
-13.35% 27.29B
CATHAY FINANCIAL HOLDING CO., LTD. Stock Cathay Financial Holding Co., Ltd.
+19.78% 25.43B
Other Life & Health Insurance
  1. Stock Market
  2. Equities
  3. 000627 Stock
  4. Financials Hubei Biocause Pharmaceutical Co., Ltd.